Medication Assisted Treatment for Opioid Dependence (MATOD) clinical observation opportunity

April 14, 2026

SEMPHN is excited to offer a new paid opportunity for accredited practitioners wanting to gain real-world experience in Medication Assisted Treatment of Opioid Dependence (MATOD). 

Developed in collaboration with Alfred Mental and Addiction Health (AMAH), the MATOD Clinical Placement Program is designed to build the skills and confidence of GPs and NPs who want to provide quality MATOD services to patients who live with Opioid Use Disorder. This new learning opportunity offers funded placements in clinical observation across AMAH’s Specialist Pharmacotherapy Service. 

Program structure:

  • Placements to be offered to GPs and NPs Victoria Wide.
  • Optimal placement for observers is 8x half days for GPs and 4x full days for NPs. This will vary and depend on available activities and your capacity.
  • Placement activities to be agreed prior to start of placement, to support coordination and ensure capacity for discussion and reflection of observation.

Benefits of the program:

  • Hands-on, real-world learning in a highly supportive specialist environment.
  • Start prescribing at a time when your involvement has potential to make a big impact.
  • Generous remuneration for training time.
  • Build on prior MATOD training and experience.
  • Guaranteed exposure to MATOD prescribing.
  • Fit the program into your working week.

To apply please contact - A4PN@semphn.org.au 

Download the flyer

Latest news

May 4, 2026
New community resource kit providing ready-to-share information on the recent changes to bulk billing and how to find your nearest bulk billing practice.
May 4, 2026
New statewide referral criteria for 12 children’s orthopaedics conditions came into effect on 20 April 2026 in all Victorian public hospitals. The children’s orthopaedics suite joins 20 suites of specialist referral criteria already in existence across Victoria.
April 29, 2026
A statewide investigation has found no evidence of an increased risk of giant cell arteritis (GCA) following COVID-19 vaccination, providing reassurance for clinicians counselling patients about vaccine safety.